These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Gukasyan N; Nayak SM Transcult Psychiatry; 2022 Oct; 59(5):652-664. PubMed ID: 33499762 [TBL] [Abstract][Full Text] [Related]
4. Expectancy in placebo-controlled trials of psychedelics: if so, so what? Butler M; Jelen L; Rucker J Psychopharmacology (Berl); 2022 Oct; 239(10):3047-3055. PubMed ID: 36063208 [TBL] [Abstract][Full Text] [Related]
5. Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. Schipper S; Nigam K; Schmid Y; Piechotta V; Ljuslin M; Beaussant Y; Schwarzer G; Boehlke C Cochrane Database Syst Rev; 2024 Sep; 9(9):CD015383. PubMed ID: 39260823 [TBL] [Abstract][Full Text] [Related]
7. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Hartogsohn I J Psychopharmacol; 2016 Dec; 30(12):1259-1267. PubMed ID: 27852960 [TBL] [Abstract][Full Text] [Related]
8. Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture. Hartogsohn I Transcult Psychiatry; 2022 Oct; 59(5):579-591. PubMed ID: 35818775 [TBL] [Abstract][Full Text] [Related]
9. In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials. Soliman PS; Curley DE; Capone C; Eaton E; Haass-Koffler CL Psychopharmacology (Berl); 2024 Jun; 241(6):1101-1110. PubMed ID: 38683460 [TBL] [Abstract][Full Text] [Related]
10. Psychosis and psychedelics: Historical entanglements and contemporary contrasts. Friesen P Transcult Psychiatry; 2022 Oct; 59(5):592-609. PubMed ID: 36300247 [TBL] [Abstract][Full Text] [Related]
11. The renaissance in psychedelic research: What do preclinical models have to offer. Murnane KS Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682 [TBL] [Abstract][Full Text] [Related]
12. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS BMJ; 2024 Aug; 386():e078607. PubMed ID: 39168500 [TBL] [Abstract][Full Text] [Related]
14. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Aday JS; Heifets BD; Pratscher SD; Bradley E; Rosen R; Woolley JD Psychopharmacology (Berl); 2022 Jun; 239(6):1989-2010. PubMed ID: 35359159 [TBL] [Abstract][Full Text] [Related]
15. Psychedelics and the essential importance of context. Carhart-Harris RL; Roseman L; Haijen E; Erritzoe D; Watts R; Branchi I; Kaelen M J Psychopharmacol; 2018 Jul; 32(7):725-731. PubMed ID: 29446697 [TBL] [Abstract][Full Text] [Related]
16. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Barber GS; Dike CC Psychiatr Serv; 2023 Aug; 74(8):838-846. PubMed ID: 36987705 [TBL] [Abstract][Full Text] [Related]
17. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice. Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ Transcult Psychiatry; 2022 Oct; 59(5):718-724. PubMed ID: 36263521 [TBL] [Abstract][Full Text] [Related]
19. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview. Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266 [TBL] [Abstract][Full Text] [Related]
20. Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos? Dupuis D; Veissière S Transcult Psychiatry; 2022 Oct; 59(5):571-578. PubMed ID: 36263513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]